667-P: Impact of Direction of Long-Haul Travel on Glycemic Control in Adults with Type 1 Diabetes (T1D) Using Multiple Daily Injections (MDI) of Insulin

Le résumé fourni par la source

Long-haul travel (flights >6 hours) can be very disruptive for people living with type 1 diabetes (T1D) . As part of a study comparing long-acting basal insulins during long-haul travel (Bevier & Castorino, et al) , we evaluated the impact of direction of travel on glucosecontrol (Abbott Freestyle Libre Pro) . Each journey began in Honolulu (HI) with a non-stop flight to New York (NY) lasting hours with a 6-hour time difference. After 72 hours, participants returned non-stop to HI. Each subject completed round trips (using either Glargine or Insulin Degludec as the basal insulin) . Participants traveled in the same direction for either basal insulin. To assess the impact of direction of travel, data using either basal insulin were combined. Overall, 21 participants (13 women, age 34.2±15.2 years, HbA1c 7.5±1.2%) completed both journeys. CGM-derived metrics comparing (a) initial 72 hours at each destination, (b) during each flight and (c) for the total journey are shown below. During sleep, TIR70-180 was 56±26% travelling East to West and 66±26% going from West to East. Although there were no significant differences in CGM-derived metrics irrespective of direction of travel, the data suggest that achieving the recommended time in range between 70-180 mg/dl is elusive for adults with T1D using MDI when travelling across multiple time zones. Disclosure W.C.Bevier: Research Support; Abbott Diabetes. H.Liu: Employee; Abbott Diabetes. K.N.Castorino: Consultant; Lilly Diabetes, Research Support; Abbott Diabetes, Dexcom, Inc., Drawbridge Health, Inc., Eyenuk, Inc., Laxmi Therapeutic Devices, Medtronic, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Speaker's Bureau; Dexcom, Inc. D.Kerr: Advisory Panel; Abbott Diabetes, Novo Nordisk A/S, Sanofi, Consultant; Evidation Health, Research Support; Novo Nordisk A/S, Stock/Shareholder; Glooko, Inc., Hi.Health. Funding Novo Nordisk Investigator Sponsored Study - ISS-001227

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.